- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05294406
Intermittent Preventive Treatment With Dihydroartemisinin-piperaquine in Papua, Indonesia (STOPMiP-2)
Evaluation of a Pilot Implementation of Intermittent Preventive Treatment With Dihydroartemisinin-piperaquine to Prevent Adverse Birth Outcomes in Papua, Indonesia
Malaria in pregnancy is a major cause of maternal and neonatal death in Papua, Indonesia. A recent trial in Papua showed that monthly intermittent preventive treatment (IPTp) with the long-acting artemisinin-based combination dihydroartemisinin-piperaquine (DP) among pregnant women in the second and third trimester was safe, tolerable and more efficacious than the current policy of single screening at antenatal care (ANC) booking and treatment of rapid diagnostic test (RDT)-positive cases. The Ministry of Health (MOH) Indonesia now plans to pilot the strategy in the routine health system in Papua, Indonesia. This study will assess the programme effectiveness of IPTp-DP delivery through antenatal care services and women's adherence to the monthly 3-day DP treatment regimen in a 'real life' setting.
The study will be undertaken in ten community health centres in the lowlands and their associated health posts in Timika city. In the first 18 months, MOH will be trained to implement the intervention using quality improvement (QI) approaches to continuously strengthen service delivery, uptake and adherence through plan-do-study-act cycles. The MOH will also be supported to collect safety data for pharmacovigilance. A mixed-methods evaluation will be conducted towards the end of the pilot using exit interviews to assess delivery effectiveness, home visits to assess adherence, and qualitative research to explore provider perceptions of the drivers of successful integration and scalability, and user acceptability. The primary outcome is adherence, defined as the proportion of pregnant women who receive the first dose of IPTp-DP by directly observed therapy (DOT) at ANC, have received the correct number of DP tablets for subsequent doses, and when visited at home have verified they completed the course. The net cost-effectiveness of implementing IPTp-DP and of the current policy of single screening and treatment (SST) in the routine health system will be assessed and compared. Net cost-effectiveness means that cost savings from averted malaria will be deducted from the intervention costs. The incremental financial cost of implementing IPTp-DP from the provider (MOH) perspective at scale in Papua, Indonesia, will also be estimated.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Papua
-
Timika, Papua, Indonesia, 99910
- Yayasan Pengembangan Kesehatan dan Masyarakat Papua
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Health facilities (pilot implementation)
- Antenatal services must be operational and accessible
- Midwives/nurses have been trained to prescribe IPTp-DP
Healthcare providers
- Healthcare providers responsible for providing antenatal care services, and facility managers
- District and provincial health managers
Pregnant women
- Pregnant women aged 15-49 years
- Women in 2nd/3rd trimester of pregnancy
- HIV negative (where status is known)
Community members
- community leaders
- community health care workers
- husbands of pregnant women
Exclusion Criteria:
Health facilities (pilot implementation)
- Health facilities which have accessibility issues and will not be enrolled in the pilot.
Healthcare providers
- Health workers providing ANC and IPTp-DP services in health facilities who have provided services for <1 month.
Pregnant women
- Women with communication or language problems including not being able to speak Indonesian.
- Pregnant women who are unwell during interview
- Pregnant women who move outside the pilot implementation areas.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IPTp-DP
Pregnant women attending routine antenatal care visits in their second and third trimester are given a monthly, presumptive treatment dose of dihydroartemisinin-piperaquine of three tablets daily for three days (9 tablets).
The first dose is given by directly observed therapy (DOT), and the remaining doses given to the women to take at home.
|
Pregnant women attending routine antenatal care visits in their second and third trimester are given monthly IPTp consisting of a treatment dose of dihydroartemisinin-piperaquine (3 tablets per day for 3 days, 9 tablets total)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence in pregnant women
Time Frame: At study completion, an average of 10 months
|
The proportion of pregnant women who receive the first dose of IPTp-DP by DOT at ANC clinic and have the correct number of DP tablets for subsequent doses on exiting, who when visited at home verify they have completed the treatment (self report and pill counts)
|
At study completion, an average of 10 months
|
Delivery effectiveness
Time Frame: At study completion, an average of 10 months
|
The proportion of women attending ANC clinic treated appropriately according to the IPTp-DP guidelines, defined as the first dose given by directly observed therapy (DOT) on day-1 plus adequate doses to take home for days 2 and 3. Women's understanding of the treatment regimens given during that ANC visit will also be assessed.
|
At study completion, an average of 10 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Delivery effectiveness
Time Frame: At study completion, an average of 10 months
|
The proportion of women attending ANC clinic treated appropriately according to the IPTp-DP guidelines, defined as the first dose given by directly observed therapy (DOT) on day-1 plus adequate doses to take home for days 2 and 3. Women's understanding of the treatment regimens given during that ANC visit will also be assessed.
|
At study completion, an average of 10 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jenny Hill, MSc, PhD, LSTM
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21-054
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria in Pregnancy
-
University of CalgaryJimma University; Armauer Hansen Research Institute, Ethiopia; Amhara Public...RecruitingMalaria | Malaria in Pregnancy | Pregnancy MalariaCanada, Ethiopia
-
Centro de Investigação em Saúde de ManhiçaUniversity of California, San Francisco; Barcelona Institute for Global Health and other collaboratorsRecruitingMalaria | Malaria in Pregnancy | Malaria,FalciparumMozambique
-
Federal Medical Centre, OwoUnknownPregnancy | Malaria in PregnancyNigeria
-
Menzies School of Health ResearchLiverpool School of Tropical Medicine; University of Melbourne; Curtin University and other collaboratorsRecruitingPregnancy Related | Malaria | Malaria in PregnancyPapua New Guinea
-
JhpiegoBarcelona Institute for Global HealthCompletedMalaria in PregnancyCongo, The Democratic Republic of the, Madagascar, Mozambique, Nigeria
-
Centers for Disease Control and PreventionJhpiego; Ministry of Health, TanzaniaTerminatedMalaria | Malaria in PregnancyTanzania
-
JhpiegoCenters for Disease Control and Prevention; Rwanda Malaria and Other Parasitic...CompletedMalaria in PregnancyRwanda
-
Centers for Disease Control and PreventionKamuzu University of Health SciencesCompletedMalaria in PregnancyMalawi
-
Foundation for Innovative New Diagnostics, SwitzerlandWorld Health Organization; World Bank; UNICEF; United Nations Development ProgrammeUnknownMalaria | Malaria in Pregnancy | Placental MalariaBurkina Faso, Uganda
-
JhpiegoBarcelona Institute for Global HealthCompletedMalaria in PregnancyCongo, The Democratic Republic of the, Madagascar, Mozambique, Nigeria
Clinical Trials on Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine
-
Liverpool School of Tropical MedicineUniversity of Copenhagen; University of Toronto; Centers for Disease Control... and other collaboratorsCompletedPregnancy; HIV; MalariaKenya
-
London School of Hygiene and Tropical MedicineDBL -Institute for Health Research and DevelopmentCompletedBirth Weight | Anaemia | Malaria ParasitaemiaBurkina Faso
-
Liverpool School of Tropical MedicineLondon School of Hygiene and Tropical Medicine; University of Bergen; Kamuzu... and other collaboratorsCompletedMalaria in Pregnancy | Adherence, TreatmentKenya
-
Washington University School of MedicineThe Children's Investment Fund FoundationCompletedNutrition Disorders | Pregnancy | Stunting | Malnutrition in PregnancySierra Leone
-
London School of Hygiene and Tropical MedicineLiverpool School of Tropical Medicine; Medical Research Council Unit, The Gambia and other collaboratorsCompletedPregnancy | Malaria | AnaemiaBurkina Faso, Ghana, Gambia, Mali
-
London School of Hygiene and Tropical MedicineCentre national de recherche et de formation sur le paludisme; Malaria Research...Completed
-
London School of Hygiene and Tropical MedicineDepartment of State for Health and Social Welfare, The GambiaCompleted
-
International Food Policy Research InstituteAFRICSanté; UNICEF; World VisionCompletedWasting | Acute Malnutrition in ChildhoodMali
-
Barcelona Institute for Global HealthCentro de Investigação em Saúde de Manhiça; Medicines for Malaria Venture; University... and other collaboratorsRecruitingMalariaMozambique, Sierra Leone, Togo
-
Memorial Sloan Kettering Cancer CenterTufts Medical Center; Lahey ClinicCompleted